Aphria and MassRoots Partner in One of First International Collaborations between Cannabis Companies
LEAMINGTON, Ontario, Oct. 18, 2016 /PRNewswire/ -- Aphria Inc. ("Aphria" or the "Company"
(TSX-V: APH or USOTCQB:
APHQF
) one of the leading Canadian licensed producers of medical cannabis, and MassRoots, Inc. (OTCQB:
MSRT
), one of the largest technology platforms for the cannabis industry, are pleased to announce they have entered into one of the first international partnerships between cannabis companies. Under the terms of the agreement, MassRoots will help build awareness of the Aphria brand amongst its Canadian userbase. Aphria will compensate MassRoots a cash fee (in U.S. dollars) per patient it refers.
"We are thrilled to partner with Aphria to help expand their patient base while opening a new revenue stream for our business," stated MassRoots CEO Isaac Dietrich. "As a technology platform, MassRoots is available in every state and country that regulates the production of cannabis and we could not be more excited to have a partner of Aphria's caliber in the Canadian market."
"This partnership with MassRoots offers a fresh, innovative way to expand Aphria's patient base while helping to grow our digital presence," stated Aphria CEO Vic Neufeld. "MassRoots has the potential to be the leading technology platform in the cannabis sector and we look forward to leveraging their distribution channels and data to optimize our operations."
On Monday, October 17, 2016, Aphria, Inc. invested $250,000 USD in MassRoots by purchasing 500,000 shares of MassRoots common stock, along with receiving warrants to purchase an additional 500,000 shares at $0.90 per share, valid until October 17, 2019 under MassRoots' Registered Offering declared effective by the United States Securities and Exchange Commission on August 11, 2016. The partnership with MassRoots and the related equity investment remain remain subject to regulatory approvals, including the approval of the TSX Venture Exchange.
About Aphria
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, the growth of MassRoots' business, the growth of Aphria's business, potential partnerships, new features, related business strategies, statements with respect to internal expectations, estimated margins, expectations for future growing capacity, the expected growth of production facilities in North America, any commentary related to the legalization of marijuana and the timing related thereto, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria or MassRoots to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the "Exchange" nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Our mailing address is:
MassRoots
1624 Market St
Ste 201
Denver, CO 80202
LEAMINGTON, Ontario, Oct. 18, 2016 /PRNewswire/ -- Aphria Inc. ("Aphria" or the "Company"
(TSX-V: APH or USOTCQB:
APHQF
) one of the leading Canadian licensed producers of medical cannabis, and MassRoots, Inc. (OTCQB:
MSRT
), one of the largest technology platforms for the cannabis industry, are pleased to announce they have entered into one of the first international partnerships between cannabis companies. Under the terms of the agreement, MassRoots will help build awareness of the Aphria brand amongst its Canadian userbase. Aphria will compensate MassRoots a cash fee (in U.S. dollars) per patient it refers. "We are thrilled to partner with Aphria to help expand their patient base while opening a new revenue stream for our business," stated MassRoots CEO Isaac Dietrich. "As a technology platform, MassRoots is available in every state and country that regulates the production of cannabis and we could not be more excited to have a partner of Aphria's caliber in the Canadian market."
"This partnership with MassRoots offers a fresh, innovative way to expand Aphria's patient base while helping to grow our digital presence," stated Aphria CEO Vic Neufeld. "MassRoots has the potential to be the leading technology platform in the cannabis sector and we look forward to leveraging their distribution channels and data to optimize our operations."
On Monday, October 17, 2016, Aphria, Inc. invested $250,000 USD in MassRoots by purchasing 500,000 shares of MassRoots common stock, along with receiving warrants to purchase an additional 500,000 shares at $0.90 per share, valid until October 17, 2019 under MassRoots' Registered Offering declared effective by the United States Securities and Exchange Commission on August 11, 2016. The partnership with MassRoots and the related equity investment remain remain subject to regulatory approvals, including the approval of the TSX Venture Exchange.
About Aphria
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, the growth of MassRoots' business, the growth of Aphria's business, potential partnerships, new features, related business strategies, statements with respect to internal expectations, estimated margins, expectations for future growing capacity, the expected growth of production facilities in North America, any commentary related to the legalization of marijuana and the timing related thereto, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria or MassRoots to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange (the "Exchange"
nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Our mailing address is:
MassRoots
1624 Market St
Ste 201
Denver, CO 80202
